Coherus Biosciences: Five Readouts Or More Possible In 2026 (NASDAQ:CHRS)

Core Insights - Coherus Oncology (NASDAQ: CHRS) has shown significant revenue growth from its product Loqtorzi (toripalimab) in Q2 2025 compared to Q1 2025, indicating a positive trend in its financial performance [1] - The company is approaching important milestones related to its developmental pipeline, which could further impact its market position and revenue potential [1] Company Performance - The revenue growth from Loqtorzi in Q2 2025 is described as more compelling than in the previous quarter, suggesting an upward trajectory in sales [1] - The upcoming major readouts from the company's developmental pipeline are anticipated to be critical for future growth and investor interest [1]